Medytox Investments

Medytox, Inc. is a biopharmaceutical company specializing in the research, development, and manufacturing of medical aesthetic products. Its core offerings include various botulinum toxin-based injections, such as Neuronox and Meditoxin, alongside a portfolio of hyaluronic acid dermal fillers like Neuramis. The company employs advanced biopharmaceutical capabilities to innovate in the field of neurotoxins and tissue augmentation.

Founded in 2000 by Hyunho Jung, Medytox originated from an ambition to pioneer the development of botulinum toxin-based treatments in South Korea. Jung's insight recognized the significant potential for these compounds in medical applications, leading to the company's establishment as a venture focused on biopharmaceutical innovation and product commercialization.

Medytox’s products serve the medical aesthetic market, primarily used by clinicians and specialists for procedures enhancing appearance. The company envisions itself as a global leader within the biopharmaceutical sector, driven by continuous research and development to expand its influence and product pipeline in the aesthetic and therapeutic realms.